Roche announced that it has entered into four new technology transfers with local manufacturing companies in Africa and Asia; Regal Pharmaceuticals in Kenya, CAPS Holdings in Zimbabwe, Shelys Pharmaceuticals in Tanzania and Beximco Pharmaceuticals Ltd in Bangladesh. As part of Roche's Technology Transfer Initiative, these companies will be provided free of charge with the technical expertise to manufacture generic HIV medicine, based upon the processes to produce saquinavir, Roche's 2nd linel HIV medicine.
Since its launch two years ago, Roche has signed Technology Transfer agreements with a total of nine companies across sub-Saharan Africa and the world's Least Developed Countries. Furthermore Roche has received expressions of interest from a total of 35 manufacturers in 15 eligible countries, including Kenya, Ghana, Zimbabwe and Nigeria. Roche will continue to work with these individual applicants to assess production capabilities.
In addition to these four new agreements, Roche has expanded the Technology Transfer Initiative with training seminars for local manufacturers across sub-Saharan Africa and the world's Least Developed Countries. These sessions focus on the development of improved manufacturing processes and provide a forum for Roche to share its knowledge and experience with those who have access to fewer resources. The knowledge gained by local manufacturers enables them to strengthen their manufacturing capability, increase manufacturing knowledge on the production of medicines beyond HIV.
Rahul Malhotra, CEO Shelys Pharmaceuticals, Tanzania commented: "The practical support that Roche has provided has been a great learning experience for my team, enabling us to make improvements to our entire technical and quality systems. We have been enthused by this partnership and are eager to work with Roche on this initiative to help meet the needs of our people suffering from HIV infections, and improve availability of these badly needed medications."
Roche's dedicated team will work onsite at manufacturing facilities at all four locations and from its headquarters in Switzerland to undertake the technology transfers. The companies will be able to produce saquinavir for supply throughout countries in sub-Saharan Africa, and to those defined as Least Developed by the United Nations, due to Roche's policy of not filing patents on antiretroviral medicines in these countries.
Since its launch two years ago, Roche has signed Technology Transfer agreements with a total of nine companies across sub-Saharan Africa and the world's Least Developed Countries. Furthermore Roche has received expressions of interest from a total of 35 manufacturers in 15 eligible countries, including Kenya, Ghana, Zimbabwe and Nigeria. Roche will continue to work with these individual applicants to assess production capabilities.
In addition to these four new agreements, Roche has expanded the Technology Transfer Initiative with training seminars for local manufacturers across sub-Saharan Africa and the world's Least Developed Countries. These sessions focus on the development of improved manufacturing processes and provide a forum for Roche to share its knowledge and experience with those who have access to fewer resources. The knowledge gained by local manufacturers enables them to strengthen their manufacturing capability, increase manufacturing knowledge on the production of medicines beyond HIV.
Rahul Malhotra, CEO Shelys Pharmaceuticals, Tanzania commented: "The practical support that Roche has provided has been a great learning experience for my team, enabling us to make improvements to our entire technical and quality systems. We have been enthused by this partnership and are eager to work with Roche on this initiative to help meet the needs of our people suffering from HIV infections, and improve availability of these badly needed medications."
Roche's dedicated team will work onsite at manufacturing facilities at all four locations and from its headquarters in Switzerland to undertake the technology transfers. The companies will be able to produce saquinavir for supply throughout countries in sub-Saharan Africa, and to those defined as Least Developed by the United Nations, due to Roche's policy of not filing patents on antiretroviral medicines in these countries.
No comments:
Post a Comment